Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
In Reply We appreciate the comments of Tomlinson and Smeeth concerning that the differential misclassification would tend to bias our results toward favoring angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB) use in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. We performed additional analyses to address the question raised in the letter. However, their speculation is not evidenced by the further analysis from our cohort.
Hsu C, Liu J, Tarng D. Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and Renal Outcomes—Reply. JAMA Intern Med. 2014;174(10):1706-1707. doi:10.1001/jamainternmed.2014.1578